Curis Q3 2023 Earnings Report
Key Takeaways
Curis, Inc. reported a net loss of $12.2 million for Q3 2023, with revenues of $2.8 million from royalties. The company is advancing its clinical development of emavusertib, with ongoing trials and upcoming data presentations.
Re-started patient enrollment in both the Phase 1/2 TakeAim Leukemia monotherapy and TakeAim Lymphoma combination studies after the removal of the partial clinical hold.
Expects to initiate a triplet combination study in AML in the fourth quarter.
Will present updated data from the TakeAim Lymphoma combination study at ASH in December.
Cash, cash equivalents and investments totaled $68.5 million, expected to fund operations into 2025.
Curis
Curis
Forward Guidance
Curis expects its existing cash, cash equivalents and investments to enable its planned operations into 2025.